Mercer Global Advisors
CDTX

Mercer Global Advisors’s Cidara Therapeutics CDTX Stock Holding History

Mercer Global Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,438
Closed -$27K – 2018
2023
Q3 		$27K Buy
+1,438
New +$28.2K ﹤0.01% 1914

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Mercer Global Advisors's CDTX Position: Q4 2023 in Review

Mercer Global Advisors sold out of Cidara Therapeutics (CDTX) in Q4 2023, closing a stake of 1,438 shares — an estimated $27K sold.

Mercer Global Advisors first reported a position in CDTX in Q3 2023 and held it in 1 quarter. The position peaked at $27K in Q3 2023. 51 funds tracked by Wall St. Rank hold CDTX as of Q4 2023.

  • Mercer Global Advisors reported no remaining Cidara Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Mercer Global Advisors sold 1,438 Cidara Therapeutics shares in Q4 2023, an estimated $27K.
  • Mercer Global Advisors first reported a position in Cidara Therapeutics in Q3 2023 and held it in 1 quarter.
  • Mercer Global Advisors's Cidara Therapeutics position peaked at $27K in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2023.

Based on Mercer Global Advisors's 13F filing for Q4 2023, filed 15 Feb 2024.